Slideshow

Antipsychotic Augmentation vs Monotherapy in Schizophrenia

Author(s):

Brian Miller, MD, PhD, MPH

To augment or not to augment? That is the question.

View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.

Related Videos
brain connections
schism
electric brain
DBS
schizophrenia
sc
schizophrenia
clozapine
brain
cognition
Related Content
depression
May 1st 2025

FDA Filing Fee Waiver for New Drug Application of NRX-100 for Suicidal Depression

Leah Kuntz
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
Parkinson disease
April 25th 2025

Depression, Apathy, and Anxiety in Parkinson Disease

Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
Blue Light Blockers: A Behavior Therapy for Mania
October 7th 2021

Blue Light Blockers: A Behavior Therapy for Mania

Chris Aiken, MD Kellie Newsome, PMH-NP
schizophrenia
April 22nd 2025

Cobenfy as Add-On Treatment for Schizophrenia Fails to Meet Primary Endpoint in Phase 3 ARISE Trial

Leah Kuntz
business partners
April 22nd 2025

Cybin Announces Partnership With Osmind to Advance Clinical-Stage Psychiatry Programs

Leah Kuntz
© 2025 MJH Life Sciences

All rights reserved.